Immunic, Inc. (NASDAQ:IMUX) Stock Has Average Target Price of $35.43 According to Brokerages

Posted by Francis Steltz on Nov 8th, 2026

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has been given a consensus rating of “Buy” by the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and four have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $35.43.

Several equities research analysts have recently weighed in on the company. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Zacks Research raised Immunic from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Cantor Fitzgerald started coverage on Immunic in a report on Friday, October 23rd. They issued an “overweight” rating for the company. Finally, Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th.

Get Our Latest Report on IMUX

Immunic Price Performance

NASDAQ IMUX opened at $7.75 on Tuesday. The firm has a market capitalization of $105.71 million, a P/E ratio of -1.77 and a beta of 1.48. Immunic has a 1-year low of $5.06 and a 1-year high of $17.43. The business’s 50-day simple moving average is $9.37 and its 200-day simple moving average is $11.49.

Immunic (NASDAQ:IMUX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. On average, equities research analysts expect that Immunic will post -3.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunic

Institutional investors have recently added to or reduced their stakes in the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Immunic in the first quarter worth about $27,000. ADAR1 Capital Management LLC purchased a new stake in Immunic during the 1st quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. increased its holdings in Immunic by 21.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock worth $69,000 after purchasing an additional 1,400 shares during the last quarter. Bank of America Corp DE raised its position in shares of Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares in the last quarter. Finally, Alps Advisors Inc. raised its position in shares of Immunic by 28.0% in the 3rd quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after purchasing an additional 3,870 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

(Get Free Report)

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies.

Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.